Supported by $6.4 million in private funding, the Neuroscape neuroscience center investigates the experiential side of psychedelic therapies.
Researchers in Denmark shed light on psilocybin’s neurological effects after administering the substance to pigs in a recent study.
This column is the first of a regular series offering advice in response to reader questions about psychedelics by DanceSafe Executive Director Mitchell Gomez and Programs and Communications Coordinator Rachel Clark.
TrPR Program takes an interdisciplinary and inclusive approach to investigating psychedelic-assisted therapies for higher risk patients.
A recent study finds that more psychedelic users report better physical health than those who’ve never used psychedelic substances.
The world’s largest drug survey has found that some people are using psychedelics on their own to address mental health concerns.
Scientists have established real-time, two-way communication with people having lucid dreams, an experience that, according to two dream experts, is distinctly psychedelic in nature.
The NYU Langone Center for Psychedelic Medicine will conduct scientific analysis and train investigators how to conduct clinical research and preclinical research on psychedelic compounds.
Comments in support of ethical guidelines for ketamine clinicians stir pointed disagreements about integrative care and treatment for psychiatric indications.
A recent study shows that LSD makes neuronal pathways in the brain more flexible, creating new connections typically not allowed by the brain’s rigid structure.